title: [Comparison of the effectiveness of olicard 40 retard and cardonit 40 prolongatum preparations in treatment of stable coronary heart disease].
abstract: The purpose of the work was a comparison of the effectiveness of representatives of two subgroups of nitrates: Olicard 40 (isosorbide mononitrate) and Cardonit 40 (isosorbide dinitrate) in the treatment of ischaemic heart disease. The studied group consisted of 52 patients with stable coronary heart disease who were given for 30 days according to "blind trial" rules either Cardonit 40 or Olicard 40 in single daily dose. The effects of the treatment were monitored, assessing the parameters during three exercise tests and two 24-hour records by the Holter method. The advantage of Olicard 40 was demonstrated, expressed by higher effectiveness in the treatment of coronary heart disease (especially its "silent" form) without development of tachyphylaxis and with lower per cent of adverse reactions.
authors.affiliation: I Kliniki Chorób Wewnetrznych i Kardiologii Instytutu Medycyny Wewnetrznej Ak. Med., Lodzi.
authors.forename: M
authors.initials: M
authors.lastname: Kurpesa
authors.forename: M
authors.initials: M
authors.lastname: Krzemińska-Pakuła
authors.forename: E
authors.initials: E
authors.lastname: Kedzia
authors.forename: E
authors.initials: E
authors.lastname: Trzos
authors.forename: W
authors.initials: W
authors.lastname: Musiał
authors.forename: Z
authors.initials: Z
authors.lastname: Peruga
mesh_terms: D000328:Adult; D003327:Coronary Disease / Q000188:drug therapy* / Q000503:physiopathology; D003692:Delayed-Action Preparations; D005080:Exercise Test; D005260:Female; D006801:Humans; D007548:Isosorbide Dinitrate / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D003692:Delayed-Action Preparations; D014665:Vasodilator Agents; D007548:Isosorbide Dinitrate; C030397:isosorbide-5-mononitrate
vernacular_title: Porównanie skuteczności preparatów Olicard 40 retard i Cardonit 40 prolongatum w leczeniu stabilnej choroby wieńcowej.